Objective：To analyze the efficacy of taurochenodeoxycholic acid（TCDCA）on intestinal inflammation and to provide a theoretical basis for the treatment of acute and chronic intestinal inflammation. Methods：In the in vitro and in vitro experiments，the cells and animals were devided into the control group，lipopolysaccharide（LPS）group，and LPS + TCDCA group. In the in vitro experiments，MTT method was firstly applied to screen the appropriate working concentration of TCDCA，and then LPS stimulation was given to the LPS group，and LPS and TCDCA stimulation were given to the LPS + TCDCA group subsequently. The expression of inflammation-related mRNAs and proteins were examined by RT-qPCR and Western blot，respectively . In the in vivo experiments，the LPS group was injected with LPS solution intravenously through the ear margin of rabbits，and the LPS+TCDCA group was treated as above and then fed with TCDCA solution through drinking water. Histopathological alterations of the samples were assessed by HE staining，periodic acid-Schiff staining and Alcian blue-nuclear fast red staining after experimental sampling. Results：The results of in vitro experiments showed that the expression of tumor necrosis factor-α，interleukin-1β，interleukin-6，and interferon-γ indexes was significantly reduced and the expression of interleukin-10 indexes was elevated in macrophages in the LPS+TCDCA group compared with that in the LPS group. In the in vivo experiments，the results of HE staining showed that the inflammation of intestinal tissues was relieved，and the results of periodic acid-Schiff staining and Alcian blue-nucleic solid red staining showed that the number of cup cells and the secretion of acidic as well as neutral mucins in the LPS + TCDCA group increased compared with those in the LPS group. Conclusion：TCDCA alleviates intestinal tissue inflammation and reduces intestinal inflammatory damage caused by LPS by decreasing the expression of inflammatory factors.